Essential resources for NHS Wales e-Library users

11 August 2026

Pharmaceutical Excipients

This update contains a global pharmacopoeia update.

11 August 2026

Palliative Care Formulary

This update contains 3 revised monographs.

The following monograph has been fully revised: Drugs for Pruritus

The following monographs have been partially revised: Rifampicin; Editorial Staff.

11 August 2026

Stockley’s Interactions Checker

For August, 591 new interactions have been added, and 838 existing interactions have been updated.

11 August 2026

AHFS Drug Information

This update contains 10 new monographs and 32 revised monographs.

New monographs: Atenolol and Chlorthalidone; Baxdrostat; Bulevirtide Acetate-gmod; Cefepime Hydrochloride and Zidebactam Dihydrate; Dolutegravir Sodium, Lamivudine, and Tenofovir Disoproxil Fumarate; Naproxen and Esomeprazole; Pivekimab Sunirine-pvzy; Sonrotoclax; SUMAtriptan Succinate and Naproxen Sodium; Tramadol Hydrochloride and Acetaminophen.

Revised monographs: Acetaminophen; Adenovirus Vaccine Live Oral; Apremilast; Arsenic Trioxide; Avatrombopag Maleate; Belantamab Mafodotin-blmf; Cetirizine Hydrochloride; Coagulation Factor IX (Recombinant); Darolutamide; DOBUTamine Hydrochloride; Dupilumab; Elinzanetant; Escitalopram Oxalate; Etripamil; Granisetron; Ketotifen Fumarate; Landiolol Hydrochloride; Levocetirizine Dihydrochloride; Mirdametinib; Mitapivat Sulfate; Modafinil; Nalmefene Hydrochloride; Niraparib Tosylate; Nirmatrelvir and Ritonavir; Palbociclib; Pentazocine Hydrochloride and Naloxone Hydrochloride; Plozasiran Sodium; Ramipril; Roflumilast (Topical); Sulopenem Etzadroxil and Probenecid; Tick-borne Encephalitis Vaccine; Vasopressin.

11 August 2026

BNF for Children

This update contains 5 significant changes, 1 dose change, 1 classification change, 2 new monographs and 2 new preparations.

Significant Changes:

• Diphtheria with tetanus, pertussis, hepatitis B, poliomyelitis and haemophilus influenzae type b vaccine: name change to diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and haemophilus influenzae type b vaccine.
• European viper snake venom antiserum: name change to european viper snake venom antisera.
• Mepolizumab: new indication and dose for eosinophilic granulomatosis with polyangiitis.
• Tranexamic acid: new important safety information on serious adverse effects due to administration errors.
• Varicella-zoster vaccine: name change to varicella vaccine.

Dose Changes:

• Vitamins A, C and D [update to age range].

Classification Changes:

• Mepolizumab [primary classification changed to Interleukin inhibitors].

New Monographs:

• Enflonsia® [clesrovimab].
• Exdensur® [depemokimab].

New Preparations: Jakavi® oral solution [ruxolitinib]; Opzelura® cream [ruxolitinib].

11 August 2026

British National Formulary

This update contains 17 significant changes, 1 dose change, 3 classification changes, 3 new monographs, 3 new preparations and 4 deleted preparations.

Significant Changes:

• Chronic obstructive pulmonary disease: updated guidance on the use of dupilumab.
• Conjugated oestrogens: contra-indications, cautions, and hepatic impairment information reviewed.
• Diphtheria with tetanus, pertussis, hepatitis B, poliomyelitis and haemophilus influenzae type b vaccine: name change to diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and haemophilus influenzae type b vaccine.
• Estradiol (Estring®): indication changed from postmenopausal urogenital conditions (not suitable for vasomotor symptoms or osteoporosis prophylaxis) to genitourinary symptoms of menopause in perimenopausal, menopausal, and postmenopausal females.
• Estradiol: indication changed from vaginal atrophy in postmenopausal women to genitourinary symptoms of menopause in perimenopausal, menopausal, and postmenopausal females; contra-indications, cautions, and hepatic impairment information reviewed.
• Estriol: indication changed from vaginal atrophy in postmenopausal women to genitourinary symptoms of menopause in perimenopausal, menopausal, and postmenopausal females; contra-indications, cautions, and hepatic impairment information reviewed.
• European viper snake venom antiserum: name change to european viper snake venom antisera.
• Herpes-zoster vaccine (recombinant, adjuvanted): name change to herpes-zoster vaccine.
• Menopause: new guidance on the management of menopause.
• Mepolizumab: new indication and dose for uncontrolled chronic obstructive pulmonary disease, severe chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
• Ospemifene: indication changed from moderate to severe symptomatic vulvar and vaginal atrophy [in post-menopausal women who are not candidates for local vaginal oestrogen therapy] to genitourinary symptoms of menopause in perimenopausal, menopausal, and postmenopausal females.
• Prasterone: indication changed from vulvar and vaginal atrophy [in postmenopausal women with moderate to severe symptoms] to genitourinary symptoms of menopause in perimenopausal, menopausal, and postmenopausal females; contra-indications and cautions reviewed.
• Sex hormones: this treatment summary has been replaced by the new Menopause treatment summary.
• Tranexamic acid: new important safety information on serious adverse effects due to administration errors.
• Urinary incontinence and pelvic organ prolapse in females: updated guidance on use of vaginal oestrogens.
• Vaginal and vulval conditions: updated guidance on use of vaginal oestrogens.
• Varicella-zoster vaccine: name change to varicella vaccine.

Dose Changes:

• Vitamins A, C and D [update to age range].

Classification Changes:

• Benralizumab [primary classification changed to Interleukin inhibitors].
• Mepolizumab [primary classification changed to Interleukin inhibitors].
• Reslizumab [primary classification changed to Interleukin inhibitors].

New Monographs:

• Exdensur® [depemokimab].
• Leqselvi® [deuruxolitinib].
• Ziihera® [zanidatamab].

New Preparations: Jakavi® oral solution [ruxolitinib]; Opzelura® cream [ruxolitinib]; Wegovy® 7.2 mg solution for injection in pre-filled pen [semaglutide].

Deleted Preparations: Bedol® [estradiol]; Elleste Solo® MX [estradiol]; Ovestin® [estriol]; Premarin® [conjugated oestrogens].